Related Experiment Video
Updated: Nov 3, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.7K
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
Jeffrey I Traylor1, Mark N Pernik1, Aaron R Plitt1
1Department of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Cancers
|June 2, 2021
Summary
Chordomas and chondrosarcomas are rare cancers resistant to standard treatments. This review explores immunotherapy targets like brachyury and PD-1 inhibition, offering new hope for these challenging neoplasms.
Area of Science:
- Oncology
- Cancer Research
- Immunotherapy
Background:
- Chordomas and chondrosarcomas are rare, aggressive tumors.
- These neoplasms exhibit resistance to chemoradiation therapy.
- Surgical resection remains the primary treatment modality.
Purpose of the Study:
- To review potential biomarkers and immunotherapy targets for chordoma and chondrosarcoma.
- To summarize current clinical evidence and ongoing trials for immunotherapy in these rare cancers.
Main Methods:
- Literature review of existing studies on chordoma and chondrosarcoma immunotherapy.
- Analysis of identified biomarkers and molecular targets.
- Overview of current and upcoming clinical trials.
Main Results:
- Brachyury is a key biomarker and immunotherapy target in chordoma.
- PD-1 inhibition is being investigated for both chordoma and chondrosarcoma.
- IDH inhibitors show emerging potential for chondrosarcoma treatment.
Conclusions:
- Immunotherapy presents a promising avenue for treating chordoma and chondrosarcoma.
- Further research and clinical trials are crucial to optimize immunotherapy strategies for these rare tumors.
Related Concept Videos
01:27Tumor Immunotherapy
797
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
797
01:30Cancer Vaccines
595
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
595
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:19Mesenchymal Stem Cells
5.2K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.2K